N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Aged (21-month-old) male CD mice given MPTP to model Parkinson's disease
- Dose used in the study
- micronised PEA (PEAm), pretreatment for 60 days; exact dose not stated in the abstract
- Duration
- 60-day pretreatment, then 4 MPTP injections over 24 hours, mice killed 7 days later
- What was measured
- Behavioural deficits, tyrosine hydroxylase and dopamine transporter expression, alpha-synuclein and beta3-tubulin, proinflammatory cytokines, hippocampal neurogenesis. Aged mice (21 months) were pretreated with micronised PEA for 60 days before four MPTP injections given over 24 hours.
What the authors reported
PEAm pretreatment lessened MPTP-induced behavioural deficits and preserved tyrosine hydroxylase and dopamine transporter expression, while blunting the rise in alpha-synuclein and beta3-tubulin in the substantia nigra. PEAm also reduced proinflammatory cytokine expression and supported hippocampal neurogenesis.
Limits of this study
An aged mouse model of Parkinson's disease; it cannot show effect in people. Funding and conflicts not stated in the abstract.
Source
PubMed 29552727 · doi:10.1007/s12035-018-0959-2
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.